Home » Topics » BioWorld Science

BioWorld Science
RSS

Zemplar approved for pediatric use

June 1, 2004

Atiprimod enters new phase I/II trial in relapsed multiple myeloma

June 1, 2004

AEterna Zentaris unveils new name, progress and plans

June 1, 2004

Anadys selects ANA-975 as development candidate for HCV

June 1, 2004

Orphan drug status for PD-6735

June 1, 2004

Enrollment under way in confirmatory phase III trial of Sebazole

June 1, 2004

FDA sets date to discuss Macugen NDA

June 1, 2004

Dosing commences in phase II trial of Albuferon for chronic HCV

June 1, 2004

Pharmaceutical Resources changes name to Par Pharmaceutical Companies

June 1, 2004

Approval for Gonal-f Pen for infertility

June 1, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...